Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2018

  • ID: 4537872
  • Report
  • 129 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Amgen Inc
  • Bayer AG
  • Eddingpharm Inc
  • Eli Lilly and Co
  • H3 Biomedicine Inc
  • Ionis Pharmaceuticals Inc
  • MORE
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2018

Summary:

According to the recently published report 'Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2018'; Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) pipeline Target constitutes close to 26 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes.

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Fibroblast growth factor receptor 4 is a protein encoded by the FGFR4 gene. It plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. It is required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. It phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades.

The report 'Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2018' outlays comprehensive information on the Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 6, 5, 1, 7 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Metabolic Disorders, Central Nervous System, Gastrointestinal and Musculoskeletal Disorders which include indications Hepatocellular Carcinoma, Solid Tumor, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Type 2 Diabetes, Lung Adenocarcinoma, Ovarian Cancer, Bladder Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Non-Small Cell Lung Cancer, Obesity, Recurrent Glioblastoma Multiforme (GBM), Squamous Non-Small Cell Lung Cancer, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Achondroplasia, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Constipation, Epithelial Ovarian Cancer, Ewing Sarcoma, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Hematological Tumor, High-Grade Glioma, Kidney Cancer (Renal Cell Cancer), Liver Cancer, Lung Cancer, Lymphoma, Metastatic Biliary Tract Cancer, Nasopharyngeal Cancer, Non-Alcoholic Steatohepatitis (NASH), Osteosarcoma, Peritoneal Cancer, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, Primitive Neuroectodermal Tumor (PNET), Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Rhabdomyosarcoma, Small-Cell Lung Cancer, Spinal Cord Injury, Thymic Carcinoma, Thyroid Cancer and Transitional Cell Cancer (Urothelial Cell Cancer).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
  • The report reviews Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen Inc
  • Bayer AG
  • Eddingpharm Inc
  • Eli Lilly and Co
  • H3 Biomedicine Inc
  • Ionis Pharmaceuticals Inc
  • MORE
Introduction

Report Coverage

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Overview

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Companies Involved in Therapeutics Development

Abbisko Therapeutics Co Ltd

Amgen Inc

ArQule Inc

Bayer AG

Blueprint Medicines Corp

Eddingpharm Inc

Eisai Co Ltd

Eli Lilly and Co

Genosco Inc

H3 Biomedicine Inc

Hanmi Pharmaceuticals Co Ltd

Incyte Corp

Ionis Pharmaceuticals Inc

Johnson & Johnson

Merrimack Pharmaceuticals Inc

NGM Biopharmaceuticals Inc

Novartis AG

Principia Biopharma Inc

Tasly Pharmaceutical Group Co Ltd

Vichem Chemie Research Ltd

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Drug Profiles

ABSK-011 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLU-554 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLU-9931 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

derazantinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EDP-317 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

erdafitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ES-135 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FGF-401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

golvatinib tartrate + lenvatinib mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

H-3B6527 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-81442 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INCB-62079 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

infigratinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IONIS-463588 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lenvatinib mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-2874455 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MM-161 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NGM-282 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRN-1371 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rogaratinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit FGFR4 for Solid Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize FGFR4 for Hepatocellular Carcinoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Pan FGFR for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TSLB-1344 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Dormant Products

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Discontinued Products

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Product Development Milestones

Featured News & Press Releases

Apr 14, 2018: NGM Bio Announces Results From Phase 2 Study Of NGM282 In Nash Patients Demonstrating Clinically Significant Improvements In Liver Histology After 12 Weeks

Apr 13, 2018: NGM Bio Announces Late-Breaking Plenary Presentation At International Liver Conference 2018 Of Detailed Results From Phase 2 Study Of NGM282 In Patients With Primary Sclerosing Cholangitis

Mar 23, 2018: Anticancer Agent LENVIMA (lenvatinib mesylate) Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan, First Approval Worldwide for LENVIMA for HCC

Mar 15, 2018: Janssen Announces U.S. FDA Breakthrough Therapy Designation for Erdafitinib in the Treatment of Metastatic Urothelial Cancer

Mar 15, 2018: ArQule to Present Data on Derazantinib

Mar 12, 2018: Grupo Biotoscana Announces New Initiatives for LENVIMA

Mar 12, 2018: NGM Bio Announces Publication In The Lancet Of Phase 2 Study Of NGM282 In NASH Patients And Upcoming Presentations Of NGM282 NASH Histology Data And NGM282 PSC Data At The International Liver Congress 2018

Mar 08, 2018: Gastrointestinal Hormone Measurably Improved Symptoms of Non-Alcoholic Fatty Liver Disease

Feb 16, 2018: UK NICE Recommends Anticancer Agent Lenvima as Treatment for Thyroid Cancer

Feb 15, 2018: Positive Phase 3 Trial Results of Investigational Anticancer Agent Lenvatinib in Unresectable Hepatocellular Carcinoma (HCC) Published in The Lancet

Feb 10, 2018: Phase III Trial Results of Anticancer Agent Lenvatinib in Hepatocellular Carcinoma Published in the Lancet

Feb 05, 2018: NGM Reports Top-Line Results From Phase 2 Study Of NGM282 In Patients With Primary Sclerosing Cholangitis (PSC)

Jan 26, 2018: NICE Issues Technology Appraisal Guidance on Lenvatinib with Everolimus for Previously Treated Advanced RCC

Jan 25, 2018: Janssen to Present data on Erdafitinib at Prostate and Urothelial Cancers at ASCO GU 2018

Jan 22, 2018: Eisai Presents Results of Analysis of Phase III Trial of Lenvima (Lenvatinib) In Hepatocellular Carcinoma Based on Independent Imaging Review at ASCO-GI

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1)

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Abbisko Therapeutics Co Ltd, H1 2018

Pipeline by Amgen Inc, H1 2018

Pipeline by ArQule Inc, H1 2018

Pipeline by Bayer AG, H1 2018

Pipeline by Blueprint Medicines Corp, H1 2018

Pipeline by Eddingpharm Inc, H1 2018

Pipeline by Eisai Co Ltd, H1 2018

Pipeline by Eli Lilly and Co, H1 2018

Pipeline by Genosco Inc, H1 2018

Pipeline by H3 Biomedicine Inc, H1 2018

Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018

Pipeline by Incyte Corp, H1 2018

Pipeline by Ionis Pharmaceuticals Inc, H1 2018

Pipeline by Johnson & Johnson, H1 2018

Pipeline by Merrimack Pharmaceuticals Inc, H1 2018

Pipeline by NGM Biopharmaceuticals Inc, H1 2018

Pipeline by Novartis AG, H1 2018

Pipeline by Principia Biopharma Inc, H1 2018

Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2018

Pipeline by Vichem Chemie Research Ltd, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abbisko Therapeutics Co Ltd
  • Amgen Inc
  • ArQule Inc
  • Bayer AG
  • Blueprint Medicines Corp
  • Eddingpharm Inc
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Genosco Inc
  • H3 Biomedicine Inc
  • Hanmi Pharmaceuticals Co Ltd
  • Incyte Corp
  • Ionis Pharmaceuticals Inc
  • Johnson & Johnson
  • Merrimack Pharmaceuticals Inc
  • NGM Biopharmaceuticals Inc
  • Novartis AG
  • Principia Biopharma Inc
  • Tasly Pharmaceutical Group Co Ltd
  • Vichem Chemie Research Ltd
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll